Citius Selling General Administrative from 2010 to 2024

CTXR Stock  USD 0.13  0.04  23.53%   
Citius Pharmaceuticals Selling General Administrative yearly trend continues to be relatively stable with very little volatility. Selling General Administrative is likely to grow to about 26.5 M this year. During the period from 2010 to 2024, Citius Pharmaceuticals Selling General Administrative destribution of quarterly values had range of 26.4 M from its regression line and mean deviation of  7,294,753. View All Fundamentals
 
Selling General Administrative  
First Reported
2010-12-31
Previous Quarter
7.4 M
Current Value
7.9 M
Quarterly Volatility
2.1 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Citius Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Citius Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 234.6 K, Interest Expense of 303.6 K or Selling General Administrative of 26.5 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.08. Citius financial statements analysis is a perfect complement when working with Citius Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Citius Pharmaceuticals Correlation against competitors.
To learn how to invest in Citius Stock, please use our How to Invest in Citius Pharmaceuticals guide.

Latest Citius Pharmaceuticals' Selling General Administrative Growth Pattern

Below is the plot of the Selling General Administrative of Citius Pharmaceuticals over the last few years. It is Citius Pharmaceuticals' Selling General Administrative historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Citius Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Selling General Administrative10 Years Trend
Slightly volatile
   Selling General Administrative   
       Timeline  

Citius Selling General Administrative Regression Statistics

Arithmetic Mean9,162,364
Geometric Mean2,409,751
Coefficient Of Variation100.28
Mean Deviation7,294,753
Median7,050,059
Standard Deviation9,187,798
Sample Variance84.4T
Range26.4M
R-Value0.94
Mean Square Error9.7T
R-Squared0.89
Slope1,941,446
Total Sum of Squares1181.8T

Citius Selling General Administrative History

202426.5 M
202325.2 M
202221.9 M
202115.7 M
202011.3 M
20198.9 M
2018M

About Citius Pharmaceuticals Financial Statements

Citius Pharmaceuticals shareholders use historical fundamental indicators, such as Selling General Administrative, to determine how well the company is positioned to perform in the future. Although Citius Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Citius Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Citius Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Selling General Administrative25.2 M26.5 M

Pair Trading with Citius Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Citius Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Citius Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Citius Stock

  0.83ME 23Andme HoldingPairCorr
  0.83VALN Valneva SE ADRPairCorr
  0.62VCNX VaccinexPairCorr

Moving against Citius Stock

  0.82BMY Bristol Myers Squibb Sell-off TrendPairCorr
  0.7EWTX Edgewise TherapeuticsPairCorr
  0.69GILD Gilead SciencesPairCorr
  0.63KZR Kezar Life SciencesPairCorr
  0.44VRDN Viridian TherapeuticsPairCorr
The ability to find closely correlated positions to Citius Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Citius Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Citius Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Citius Pharmaceuticals to buy it.
The correlation of Citius Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Citius Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Citius Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Citius Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Citius Stock Analysis

When running Citius Pharmaceuticals' price analysis, check to measure Citius Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Pharmaceuticals is operating at the current time. Most of Citius Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Citius Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Pharmaceuticals' price. Additionally, you may evaluate how the addition of Citius Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.